c-Src and cooperating partners in human cancer.

By R. Ishizawar, S. Parsons. Cancer Cell, 2004

618 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Rank–rank hypergeometric overlap: identification of statistically significant overlap between gene-expression signatures (2010, background): “Elevated SRC kinase activity has been implicated in contributing to many tumor types (37).”
ERBB receptors and cancer: the complexity of targeted inhibitors (2005, background): “fcgi?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=6714">SRC tyrosine kinase, the activity of which is increased in response to EGFR and ERBB2 signalling (reviewed in Ref”
The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy (2008, background): “Epidermal growth factor receptor ( EGFR ) and ERBB2 both bind SRC to catalyse mutual kinase activatio”
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer (2006, background): “, or non-receptor tyrosine kinases (for example, Src”
Latent bone metastasis in breast cancer tied to Src-dependent survival signals (2009, background): “Although most ER breast tumors are SRS, and estrogen receptors can interact with Src (Ishizawar and Parsons, 2004), the link of SRS status with bone metastasis is independent of ER status.”